Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nusinersen in presymptomatic spinal muscular atrophy
NCT02386553Phase 2Completed
- Sponsor
- Biogen
- Start
- May 2015
- Primary completion
- Dec 2024
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of nusinersen in spinal muscular atrophy (SMA), sponsored by Biogen. Primary endpoint: Time to Death or Respiratory Intervention at 2891 days. Started May 2015; status: completed.
02
Drugs
nusinersen
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on NCT02386553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02386553.